Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 3:20 PM
Ignite Modification Date:
2025-12-25 @ 1:40 PM
NCT ID:
NCT04434092
Pre Assignment Details:
A total of 204 participants who were diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) and who had not been previously treated with a complement-inhibitor therapy were randomized in a ratio of 2:1, 135 to crovalimab (Arm A) and 69 to eculizumab (Arm B). 6 paediatric participants were enrolled into non-randomized crovalimab (Arm C).
Recruitment Details:
Participants were enrolled at centres in Argentina, Brazil, China, France, Greece, Germany, Hong Kong, Japan, Lithuania, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, Romania Republic of Korea, Singapore, Spain, Sweden, Thailand, Türkiye, Taiwan, Ukraine, and United Kingdom from 08 Oct 2020 to 16 Nov 2022. The study is ongoing.
Study:
NCT04434092
Study Brief:
Results Section:
NCT04434092